| Alexandra Shea Williams, AGNP-C | |
|
109 Bentz Rd, Piedmont, SC 29673-1412 | |
| (864) 845-5177 | |
| Not Available |
| Full Name | Alexandra Shea Williams |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Adult Health |
| Location | 109 Bentz Rd, Piedmont, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245083872 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Alexandra Shea Williams, AGNP-C 434 Christiane Way, Greenville, SC 29607-5568 Ph: () - | Alexandra Shea Williams, AGNP-C 109 Bentz Rd, Piedmont, SC 29673-1412 Ph: (864) 845-5177 |
News Archive
Pancreatic cancer is lethal in about 95% of cases mostly due to failure of first-line therapy gemcitabine. AntiCancer Inc.'s oral methioninase (AC 00619), which is in late pre-clinical development as an anti-cancer as well as an anti-aging drug, has now been shown to overcome gemcitabine resistance in mouse models of human pancreatic cancer, including AntiCancer's patient-derived orthotopic xenograft mouse models.
The U.S. Food and Drug Administration announced today the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Japanese research group led by Professor Yasuhiko Minokoshi and Dr. Tetsuya Shiuchi, scientists at the National Institute for Physiological Sciences, NIPS, Japan, found that meals stimulated with sweet taste and motivated with its anticipation regularly activates "orexin" in the brain and it stimulates muscle glucose metabolism via the sympathetic nervous system, thereby reducing blood glucose level in mice.
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company's broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors as a proffered paper presentation at the European Society of Medical Oncology 2018 Congress in Munich, Germany.
The Obesity Action Coalition (OAC) is pleased to announce the release of its newest patient- focused brochure, titled "Understanding Obesity Stigma."
› Verified 7 days ago
Mrs. Sharon Jane Barthelmes, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 115 Beattie Park Rd, Piedmont, SC 29673 Phone: 864-845-3331 Fax: 864-845-7078 | |
Jennifer Burger, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 102 Commons Blvd Ste C, Piedmont, SC 29673 Phone: 864-220-9115 | |
Kendall Dorie, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 206 Wall St, Piedmont, SC 29673 Phone: 864-269-7950 | |
Kaleigh Ivester Applewhite, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 115 Beattie Park Rd, Piedmont, SC 29673 Phone: 864-845-3331 | |
Mrs. Nancy Tinoco Farrar, APRN, AGPCNP-BC Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 202 Wall St, Piedmont, SC 29673 Phone: 864-295-8714 | |
Mrs. Maurian Jenkins, AGNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 202 Wall St, Piedmont, SC 29673 Phone: 864-295-8714 Fax: 864-295-8764 |